Patents Assigned to Boehringer Ingelheim Pharmaceuticals, Inc.
  • Patent number: 8741897
    Abstract: Compounds of Formula (IA), (IB), (IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: June 3, 2014
    Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Younes Bekkali, Rajashekhar Betageri, Michel J. Emmanuel, Abdelhakim Hammach, Christian Hanke Justus Joachim Harcken, Thomas Martin Kirrane, Jr., Daniel Kuzmich, Thomas Wai-Ho Lee, Pingrong Liu, Usha R. Patel, John Robert Proudfoot, Hossein Razavi, Doris Riether, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee Zindell
  • Patent number: 8420630
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 16, 2013
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Publication number: 20120178184
    Abstract: The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.
    Type: Application
    Filed: March 29, 2012
    Publication date: July 12, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Jianfei YANG, Frank James KING, Jun LI, Zhen Hao QI, Ming XUE
  • Patent number: 8212040
    Abstract: Compounds of Formula (IA) wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: July 3, 2012
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Rajashehar Betageri, Mario G. Cardozo, Thomas A. Gilmore, Christian Hanke Justus Joachim Harcken, Thomas Martin Kirrane, Daniel Kuzmich, John Robert Proudfoot, Doris Riether, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee M. Zindell, Hossein Razavi
  • Publication number: 20120135401
    Abstract: Methods for the diagnosis of inflammatory bowel diseases and the identification of agents useful in the treatment of such diseases based upon the agent's effect on reducing Pim-2 expression.
    Type: Application
    Filed: March 23, 2011
    Publication date: May 31, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Jun LI, Xiang John LI, Randall W. BARTON
  • Publication number: 20120114659
    Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.
    Type: Application
    Filed: November 17, 2009
    Publication date: May 10, 2012
    Applicants: MORPHOSYS AG, BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
    Inventors: Alisa Waterman, Daniel Rajotte, Tobias Litzenburger, Alexandra Kraus
  • Patent number: 8168752
    Abstract: The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: May 1, 2012
    Assignee: Boehringer Ingelheim Pharmaceutical, Inc.
    Inventors: Jianfei Yang, Frank James King, Jun Li, Zhenhao Qi, Ming Xue
  • Publication number: 20120088298
    Abstract: A method for modulating NF-?B dependent gene transcription in a cell comprised of modulating IKK? and IKK? protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-?B dependent gene transcription.
    Type: Application
    Filed: December 19, 2011
    Publication date: April 12, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Jun LI, Xiang LI, Katrina Mary CATRON
  • Patent number: 8088915
    Abstract: A method for modulating NF-?B dependent gene transcription in a cell comprised of modulating IKK? protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-?B dependent gene transcription.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: January 3, 2012
    Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Jun Li, Xiang Li, Jianfei Yang, Kenneth B. Marcu
  • Publication number: 20110301201
    Abstract: The invention relates to a new use of dabigatran etexilate of formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, and new medicament formulations which may be used for this purpose.
    Type: Application
    Filed: August 17, 2009
    Publication date: December 8, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
    Inventor: Paul Anthony Reilly
  • Publication number: 20110282693
    Abstract: An automated data processing method for obtaining clinical data for safety, efficacy, and adverse event assessments pertaining to a therapy prescribed for the treatment of a malady, comprising the step of receiving at a location remote from a plurality of patients outcome digital information pertaining to the outcome of therapies performed on said patients, and for the efficient delivery of medications to a patient ordered pursuant to an electronic prescription from a dispensary optimized for delivery of the medication.
    Type: Application
    Filed: July 27, 2011
    Publication date: November 17, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventor: Ralph C. CRAFT
  • Patent number: 7951933
    Abstract: The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof. The invention also provides methods for treating preventing and diagnosing disorders associated with expression of CD38JL.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: May 31, 2011
    Assignee: Boehringer Ingelheim Pharmaceutical, Inc.
    Inventors: Jun Li, Xiang Li, Baerbel LoSacco, Zhenhao Qi
  • Publication number: 20110124099
    Abstract: A method for modulating NF-?B dependent gene transcription in a cell comprised of modulating IKK? and IKK? protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-?B dependent gene transcription.
    Type: Application
    Filed: August 3, 2010
    Publication date: May 26, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Jun LI, Xiang LI, Katrina Mary CATRON
  • Patent number: 7932392
    Abstract: Compounds of Formula (IA) wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: April 26, 2011
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Rajashekhar Betageri, Thomas A. Gilmore, Daniel Kuzmich, John Robert Proudfoot, David S. Thomson
  • Patent number: 7914770
    Abstract: An improved suspension formulation for use in a metered-dose inhaler having a hydro-fluoro-alkane propellant is described, the improvement being the controlled addition of a small quantity of water.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: March 29, 2011
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: George DeStefano, Linda Jean Kelash-Cannavo
  • Publication number: 20110060608
    Abstract: An automated data processing method for obtaining clinical data for safety, efficacy, and adverse event assessments pertaining to a therapy prescribed for the treatment of a malady, comprising the step of receiving at a location remote from a plurality of patients outcome digital information pertaining to the outcome of therapies performed on said patients, and for the efficient delivery of medications to a patient ordered pursuant to an electronic prescription from a dispensary optimized for delivery of the medication.
    Type: Application
    Filed: August 13, 2010
    Publication date: March 10, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventor: Ralph C. CRAFT
  • Patent number: 7795272
    Abstract: Compounds of Formula (IA) and Formula (IB) where in R1 stands for the following group (the dashed line indicates the point of attachment) and R2, R3, R4, R5, R6, Y, Z, X1 and X2 are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: September 14, 2010
    Assignee: Boehringer Ingelheim Pharmaceutical, Inc.
    Inventors: Thomas Martin Kirrane, Jr., Daniel Kuzmich, John Robert Proudfoot
  • Patent number: 7790712
    Abstract: The application relates to compounds of formula Ia and analogues thereof wherein R1 to R13 and X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: September 7, 2010
    Assignee: Boehringer Ingelheim Pharmaceutical, Inc.
    Inventors: Derek Cogan, Donghong A. Gao, Daniel R. Goldberg, Craig Andrew Miller, Neil Moss, Matthew Russell Netherton, Philip Dean Ramsden, Zhaoming Xiong
  • Patent number: 7741361
    Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: June 22, 2010
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Daniel Kuzmich, Darren DiSalvo, John Robinson Regan, David S. Thomson
  • Publication number: 20100152167
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicants: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Georg DAHMANN, Frank HIMMELSBACH, Bernd KRIST, Martin LENTER, Alexander PAUTSCH, Gisela SCHNAPP, Martin STEEGMAIER, Helmut WITTNEBEN, Anthony S. PROKOPOWICZ, Walter SPEVAK, Andreas SCHOOP, Steffen STEURER